コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 platinum-refractory recurrent or metastatic squamous cell carcinoma of the head and neck.
2 n a wide variety of human cancers, including squamous cell carcinoma of the head and neck.
3 ing as adjuvant therapy for locally advanced squamous cell carcinoma of the head and neck.
4 ected as predictors of radiation response of squamous cell carcinoma of the head and neck.
5 n effort to improve outcome in patients with squamous cell carcinoma of the head and neck.
6 ct to radiation therapy in the management of squamous cell carcinoma of the head and neck.
7 nct to radiation therapy in the treatment of squamous cell carcinoma of the head and neck.
8 able stage III (n = 9) and stage IV (n = 15) squamous cell carcinoma of the head and neck.
9 ial of patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
10 ebo in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
11 with PD-L1-positive recurrent or metastatic squamous cell carcinoma of the head and neck.
12 as first-line treatment of locally advanced squamous cell carcinoma of the head and neck.
13 ng PCa, breast cancer, colorectal cancer and squamous cell carcinoma of the head and neck.
14 n the diagnosis, prognosis, and treatment of squamous cell carcinoma of the head and neck.
15 ing, and the latest multimodal management of squamous cell carcinoma of the head and neck.
16 primary tumors in those already treated for squamous cell carcinoma of the head and neck.
17 d on current understanding of the biology of squamous cell carcinoma of the head and neck.
18 platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck.
19 nsmall-cell lung cancer and the treatment of squamous cell carcinoma of the head and neck.
20 patients with nonsmall-cell lung cancer and squamous cell carcinoma of the head and neck.
21 n patients with unresected, locally advanced squamous-cell carcinoma of the head and neck.
22 n patients with unresected, locally advanced squamous-cell carcinoma of the head and neck.
23 nd thus strongly supports a role for IMRT in squamous-cell carcinoma of the head and neck.
24 ned with cisplatin therapy, in patients with squamous-cell carcinoma of the head and neck.
25 is well tolerated in recurrent or metastatic squamous-cell carcinoma of the head and neck.
26 is approved for use in colorectal cancer and squamous-cell carcinoma of the head and neck.
27 ially curative treatment of locally advanced squamous-cell carcinoma of the head and neck.
28 TP53 mutations and survival in patients with squamous-cell carcinoma of the head and neck.
29 reduced survival after surgical treatment of squamous-cell carcinoma of the head and neck.
30 in the treatment of locoregionally advanced squamous-cell carcinoma of the head and neck.
31 were compared in 32 tumor specimens of human squamous cell carcinomas of the head and neck.
32 cs differ considerably from those of mucosal squamous cell carcinomas of the head and neck.
33 egion occurs in many malignancies, including squamous cell carcinomas of the head and neck.
34 ther study in patients with stage III and IV squamous cell carcinomas of the head and neck.
35 n clinical trials assessing the treatment of squamous cell carcinomas of the head and neck.
36 MRI has traditionally been favored, such as squamous cell carcinomas of the head and neck.
37 icate aurora kinase A in the pathogenesis of squamous-cell carcinomas of the head and neck.
38 he detection of the same mutation in 5 of 21 squamous cell carcinomas of the head and neck, 1 of 2 sm
39 logically confirmed recurrent and metastatic squamous cell carcinoma of the head and neck after disea
41 previously untreated recurrent or metastatic squamous cell carcinoma of the head and neck and ECOG pe
42 progress in understanding of the biology of squamous cell carcinoma of the head and neck and of tria
44 luating a variety of malignancies, including squamous cell carcinoma of the head and neck and thyroid
45 nfirmed diagnosis of recurrent or metastatic squamous cell carcinoma of the head and neck, and had an
46 th radiotherapy for unresected stage III-IVb squamous-cell carcinoma of the head and neck, and the ro
47 marise trials of aurora kinase inhibitors in squamous-cell carcinomas of the head and neck, and discu
48 tumor suppressor gene is a frequent event in squamous cell carcinomas of the head and neck; (b) p16 i
50 tor receptor (EGFR) is a validated target in squamous-cell carcinoma of the head and neck, but in pat
52 esentation to T cells specific for PCI-13, a squamous cell carcinoma of the head and neck cell line.
53 randomized phase 3 trial of the treatment of squamous-cell carcinoma of the head and neck compared in
54 Squamous cell carcinomas of the head and neck constitute
55 ositol 3-kinase (PI3K) pathway activation in squamous cell carcinoma of the head and neck contributes
56 dentified 34,568 patients with nonmetastatic squamous cell carcinoma of the head and neck diagnosed b
57 on and postoperative radiotherapy, high-risk squamous-cell carcinoma of the head and neck frequently
58 we recruited patients with locally advanced squamous-cell carcinoma of the head and neck from 22 sit
59 we recruited patients with locally advanced squamous-cell carcinoma of the head and neck from 41 sit
62 platinum-refractory recurrent or metastatic squamous cell carcinoma of the head and neck have few tr
63 rgeted therapy approved for the treatment of squamous cell carcinoma of the head and neck (HNSCC) but
64 works contributes to the malignant growth of squamous cell carcinoma of the head and neck (HNSCC) can
65 his study was performed with 9 cell lines of squamous cell carcinoma of the head and neck (HNSCC) dif
68 nd biodistribution studies were performed in squamous cell carcinoma of the head and neck (HNSCC) xen
70 yclooxygenase-2 (COX-2) was overexpressed in squamous cell carcinoma of the head and neck (HNSCC).
71 d, or mutated in many malignancies including squamous cell carcinoma of the head and neck (HNSCC).
77 aberrations have been reported in end-stage squamous cell carcinoma of the head and neck, including
78 tumor cell line DNA from eight patients with squamous cell carcinoma of the head and neck, including
79 fectively inhibits cellular proliferation of squamous cell carcinoma of the head and neck, induces ap
83 diotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).
84 chemoradiotherapy in locoregionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN).
85 chemoradiotherapy in locoregionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN).
86 val in patients with locoregionally advanced squamous-cell carcinoma of the head and neck (LASCCHN) a
87 ients with some cancers such as lung cancer, squamous cell carcinomas of the head and neck, melanomas
88 role of EGFR inhibition in locally advanced squamous-cell carcinoma of the head and neck needs to be
89 or at least one dimension), locally advanced squamous-cell carcinoma of the head and neck (non-nasoph
90 or at least one dimension), locally advanced squamous-cell carcinoma of the head and neck (non-nasoph
91 ough losses at 9p, 3p, and 17p are common in squamous cell carcinoma of the head and neck, only the c
92 In squamous-cell carcinomas of the head and neck, overexpre
94 emotherapy in patients with locally advanced squamous cell carcinomas of the head and neck region (HN
96 litaxel is one of the most active agents for squamous cell carcinoma of the head and neck (SCCHN) and
97 gnaling appears to play an important role in squamous cell carcinoma of the head and neck (SCCHN) and
99 with tremendous enthusiasm in the therapy of squamous cell carcinoma of the head and neck (SCCHN) bas
100 ucleus enhanced its interaction with PCNA in squamous cell carcinoma of the head and neck (SCCHN) cel
102 owth factor receptor (EGFR) is a mediator of squamous cell carcinoma of the head and neck (SCCHN) dev
103 g of cervical lymph nodes from patients with squamous cell carcinoma of the head and neck (SCCHN) has
106 nd primary malignancies in patients cured of squamous cell carcinoma of the head and neck (SCCHN) in
107 ients with advanced, recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) in
108 Concurrent chemoradiotherapy (CCRT) for squamous cell carcinoma of the head and neck (SCCHN) inc
109 ng world (South Central Asia in particular), squamous cell carcinoma of the head and neck (SCCHN) is
111 eported that apoptosis of T cells induced by squamous cell carcinoma of the head and neck (SCCHN) is
120 sh tissues and cell lines from patients with squamous cell carcinoma of the head and neck (SCCHN) ove
121 monstrate here that up-regulation of CCR7 in squamous cell carcinoma of the head and neck (SCCHN) pat
123 ients with advanced, incurable, or recurrent squamous cell carcinoma of the head and neck (SCCHN) who
125 spite the dismal prognosis for patients with squamous cell carcinoma of the head and neck (SCCHN), th
126 amination of FasL expression and function in squamous cell carcinoma of the head and neck (SCCHN), wh
127 in the peripheral blood of 19 patients with squamous cell carcinoma of the head and neck (SCCHN), wi
128 ments are needed for patients with incurable squamous cell carcinoma of the head and neck (SCCHN).
129 ents with refractory metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN).
130 tly been associated with nodal metastasis of squamous cell carcinoma of the head and neck (SCCHN).
131 activated in a variety of cancers including squamous cell carcinoma of the head and neck (SCCHN).
132 ly activated in many malignancies, including squamous cell carcinoma of the head and neck (SCCHN).
133 the peripheral circulation of patients with squamous cell carcinoma of the head and neck (SCCHN).
134 rol in a variety of human cancers, including squamous cell carcinoma of the head and neck (SCCHN).
135 te leukoplakia and suppress the formation of squamous cell carcinoma of the head and neck (SCCHN).
136 motherapy for patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
137 stant failure (DF) rates in locally advanced squamous cell carcinoma of the head and neck (SCCHN).
138 treatment for patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
139 etaxel would enhance therapeutic efficacy in squamous cell carcinoma of the head and neck (SCCHN).
140 f pemetrexed, a multitargeted antifolate, in squamous cell carcinoma of the head and neck (SCCHN).
141 -naive patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN).
142 for induction treatment of locally advanced squamous cell carcinoma of the head and neck (SCCHN).
143 ble for vaccination therapy of patients with squamous cell carcinoma of the head and neck (SCCHN).
144 53 years; performance status of 0 or 1) with squamous cell carcinoma of the head and neck (SCCHN; T1-
146 Because EGFR is ubiquitously expressed in squamous cell carcinomas of the head and neck (SCCHN) an
148 advanced stage breast ductal carcinomas and squamous cell carcinomas of the head and neck (SCCHN) re
149 equent p16 gene deletions in cell lines from squamous cell carcinomas of the head and neck (SCCHN), a
150 utively expressed on 66% of freshly isolated squamous cell carcinomas of the head and neck (SCCHN).
151 peptides in patients with breast cancer and squamous cell carcinomas of the head and neck (SCCHN).
152 d can lead to accumulation of p53 protein in squamous cell carcinomas of the head and neck (SCCHN).
154 suggested that many cell lines derived from squamous cell carcinomas of the head and neck (SCCHNs) d
156 romosomal band 8p23.2 is a frequent event in squamous cell carcinomas of the head and neck, suggestin
157 titumour activity in recurrent or metastatic squamous cell carcinoma of the head and neck, supporting
159 fe for patients with recurrent or metastatic squamous cell carcinoma of the head and neck, these data
160 Patients with intermediate-stage squamous cell carcinoma of the head and neck traditional
161 ated by our laboratory in mice bearing human squamous cell carcinoma of the head and neck tumors.
162 We analyzed the role of Stat5a/b isoforms in squamous cell carcinoma of the head and neck using expre
163 djunct to radiation therapy in patients with squamous cell carcinoma of the head and neck were conduc
164 Of these, 60 patients with PD-L1-positive squamous cell carcinoma of the head and neck were enroll
166 2005, patients with recurrent or metastatic squamous-cell carcinoma of the head and neck were enroll
167 lly recurrent tumors from four patients with squamous cell carcinoma of the head and neck, were exami
168 s Radiochemotherapy for Resectable High Risk Squamous Cell Carcinoma of the Head and Neck), which had
169 ial in patients with recurrent or metastatic squamous cell carcinoma of the head and neck who progres
170 l survival in patients with locally advanced squamous cell carcinoma of the head and neck who were tr
171 y included 72 patients with locally advanced squamous cell carcinoma of the head and neck who were tr
172 dissection in the treatment of patients with squamous-cell carcinoma of the head and neck who have ad
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。